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ABSTRACT 
Objective: A simple, specific, and precise reversed phase high performance liquid chromatography method was developed and validated as per the 
ICH guidelines for the determination of Sitafloxacin in bulk and tablet dosage forms. 
Methods: The quantitation was carried out by using Symmetry C18 ((5 µm, 100X4.6 mm) column at 300
Results: The retention time of Sitafloxacin was 2.198 minutes. The linearity was observed from 5-25 μg/mL with correlation coefficient 0.9999. The 
LOD and LOQ were found to be 0.429μg/mL and 1.415μg/mL respectively. 
c with Water: Acetonitrile in ratio of 70:30 
% V/V as mobile phase. The flow rate is 0.9 mL/min and the estimation was carried out by using PDA detector at 300 nm. 
Conclusion: The Statistics data for the Sitafloxacin was concluded that the method was found to be simple, reliable, selective, reproducible and 
accurate. The method was successfully used for quality control analysis of Sitafloxacin in bulk and Pharmaceutical dosage forms. 
Keywords: Sitafloxacin (SFX), RP-HPLC, Validation.  
 
INTRODUCTION 
Sitafloxacin is an orally active of fourth generation new 
fluoroquinolone antibiotic. The chemical name of the Sitafloxacin is 
7-[(4S)-4-Amino 6-azaspiro [2, 4] heptan-6 yl]-8-chloro-6-fluoro-1-
[(2S)-2-fluorocyclopropyl]-4-oxoquinoline 3-carboxylic acid [1, 
2]which includes amino pyrrolidine substituent at C-7 and a 
fluorocyclopropyl group at N-1. It contains a chlorine substituent at 
position C-8 of the quinolone nucleus and its molecular formula is 
C19H18ClF2N3O3
 
. It is very high activity against gram-positive, gram-
negative, and anaerobic organisms [3]. It has more potentactivity 
against gram-positive and gram-negative bacteria compared to 
currently available quinolones such as Ofloxacin, ciprofloxacin,to 
sufloxacin, and sparfloxacin[4, 5, 6 ] and reduced toxicity compared 
to other fluoroquinolones. The structure of Sitafloxacin shown in 
Figure 1. SFX is active against methicillin-resistant staphylococci, 
Streptococcus pneumoniae and other type of streptococci with 
reduced susceptibility to levofloxacin and other fluoro quinolones. 
The doses are given once daily because the post-antibiotic effect 
lasts greater than 6 hours and the serum half-life is 7 hours [7, 8]. 
Some of the recently developed quinolones have shown excellent 
anti-chlamydial activity in vitro and in vivo, as well as inclinical 
studies [9]. Only one analytical method was reported in the literature, 
such as determination of sitafloxacin in human plasma by using LC-
MS/MS [10]. However literature survey reveals that, there is no method 
for estimation of sitafloxacin in bulk and pharmaceutical dosage forms 
by RP-HPLC. So we have developed and validated this method used for 










Fig. 1: Chemical structure of SFX 
MATERIALS AND METHODS 
Materials 
Sitafloxacin pure drug was obtained as a gift sample from Daiichi 
Sankyo Co., Ltd, Japan. HPLC grade Acetonitrile, and water [filtered 
through 0.2µ filters] were purchased from Merck, Mumbai, India.  
Preparation of Solutions 
Stock solution 
100 mg of Sitafloxacin pure drug was dissolved in 100 ml of HPLC 
grade water: Acetonitrile (70:30) to get a concentration of 1000 
μg/mL. 
Standard solution 
10 ml of stock solution was taken in 100 ml volumetric flask and 
diluted up to the mark with HPLC grade water to get a concentration 
of 100μg/mL. 
Sample solution 
20 tablets of Sitafloxacin were powdered and an amount of the 
powder equivalent to 100 mg of the drug was accurately weighed 
and transferred to the 100 ml volumetric flask, made up to the 
volume with diluent. The solution was placed in an ultrasonicator 
for 20 minutes and filtered through a 25 mm, 0.45 μm nylon syringe 
filter. 10 ml of this solution was taken and diluted to 100 ml by using 
a HPLC grade water to get a final concentration of 100 μg/mL. Five 
replicate sample solutions were prepared in the similar manner. 
Hplc instrumentation and conditions 
Instrumentation 
Waters HPLC system consisting of WATERS 2695 separation 
module, an inbuilt auto sampler, column oven and WATERS 2996 
(PDA) detector was employed for throughout the analysis. 
Chromatography was performed on a Symmetry C18 column. A 
sonerex sonicator was used for sonication. The data were acquired 
by using the EM Power2 software and other details of the 
instrumentation are given in Table 1. 
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Optimized chromatographic conditions 
Chromatography was performed on a Symmetry C18
S. 
No. 
 column using 
mobile phase containing mixture of Water: Acetonitrile 70:30% V/V. 
The mobile phase was filtered through membrane filter (0.45 µm), 
and vacuum degassed by sonication prior to use.  
 
Table 1: Instrumentation and Optimized chromatographic 
conditions for proposed method 
Instrumentation Optimized Chromatographic 
Conditions 
1 HPLC  Waters: 2695 Separation Module 
2 Detector  Waters: 2996 PDA  
3 Column Symmetry C18
4 




Flow rate 0.9 mL/min 
6 Injection volume 20 µL 
7 Wavelength 300 nm 
8 Run time 10 minutes 
9 Diluent Water (HPLC Grade) 
10 Mobile phase 
composition 
Water: ACN 70:30% V/V  
 
The pump pressure and run time was maintained at 1500-2000 psi 
and 10 minutes respectively. Chromatography was performed at 
ambient temperature with flow rate at 0.9 mL/min and detection 
was carried out at 300 nm. Instrumentation and optimized 
chromatographic conditions for proposed method details are shown 
in Table 1. 
RESULTS AND DISCUSSION 
Validation study of Sitafloxacin 
The Method validation was performed as per ICH guidelines for the 
determination of Sitafloxacin in bulk, and dosage forms. The method 
was validated with respect to parameters including accuracy, 
precision, linearity, robustness, specificity, system suitability, LOD 
and LOQ [11]. 
Assay of Sitafloxacin tablets 
The developed method was applied to the assay of SFX tablets. The 
drug content was estimated with an average of six determinations, 
and its results were given in Table 2. The results were similar to the 
labeled claim of market formulations. The standard and sample 
chromatograms of Sitafloxacin were shown in Figure 2 and 3 
receptively.
Table 2: Assay results of Sitafloxacin formulations 









1 M. F 1318938 1318929 100 99.96 99.96±0.12 
* Average of 6 determinations 
 
 
Fig. 2: RP-HPLC Chromatogram of Sitafloxacin 
 
 




The specificity of the proposed method was established by injecting 
the placebo and mobile phase solution in triplicate and the 
chromatograms were recorded. Comparison of chromatograms 
revealed that there were no interactions between the placebo and 
sample peaks. Finally, it was indicated that the method was specific. 
Accuracy 
The accuracy was determined by calculating the recovery of 
Sitafloxacin at 50%, 100%, and 150% and they were added to pre 
quantified sample solution. Recovery studies were carried out in the 
tablet in triplicate each in the presence of placebo. The mean 
percentage recovery of SFX at each level was not less than 99%, and 
not more than 102%. The percentage recovery of Sitafloxacin was 
found to be in the range of 100 to 101%. The results are shown in 
the Table 3. 
Precision  
Precision should be investigated by using authentic, and 
homogeneous samples. The Precision of this method was expressed 
as S. D and %RSD of series of repeated measurements. Precision of 
SFX determination by proposed method was ascertained by 
repeated analysis of homogeneous samples of Sitafloxacin standard 
solutions in the intraday under the similar conditions. The system 
precision and method precision results were shown in Table 4. 
Linearity 
Linearity of the proposed method was established by using series of 
standard solutions of Sitafloxacin at concentration levels from 5 to 
25 μg/mL, like 5, 10, 15, 20, and 25 μg/mL. These linearity studies 
are repeated in triplicate with different stock solutions. 
  
 
Graph 1: Linearity Graph of Sitafloxacin 
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The curve obtained by concentration on x-axis and peak area on y-
axis against showed linearity in the concentration range of 5-25 
μg/mL of SFX and linearity graph is shown in Graph 1. The 
regression equation was found to be Y = 98824x + 11140 with 
correlation coefficient is r2
The robustness was evaluated by the analysis of Sitafloxacin under 
different experimental conditions such as slight changes in 
chromatographic conditions like change of temperature (± 5
 = 0.9999. The Linearity and statistical 





rate (± 0.2 mL/min), and mobile phase composition (± 5%). It was 
distinguished that there were no changes in the chromatograms, and 
the parameters were within the limits, which indicates that the 
method was robust and suitable for routine use. The complete 
results are shown in Table 6 and the method is having good system 
suitability. 
This test was conducted on freshly prepared SFX standard solution 
and was used for the evaluation of the system suitability parameters 
such as retention time, area, USP tailing and theoretical plates, limit 
of detection and limit of quantification.  
Five replicate injections for a system suitability test were injected 
into the chromatographic system and results were given in Table 7. 
 
Table 3: Recovery data for the proposed RP-HPLC method 
S. No. Concentration level Amount added (μg/mL) Amount found (μg/mL) Area obtained Mean 








5.00 1908799  
100±0.57 
 








9.98 2566768  
100.13±0.67 
 








15.01 3349282  
100.06±0.27 
 
0.266 14.97 3278576 
15.05 3331193 
*S. D & %RSD is standard deviation and percentage of relative standard deviation 
 





System Precision Method Precision 
Retention Time Peak Area Retention Time  Peak Area 
1 1 2.207 1283904 2.190 1281340 
2 2 2.198 1262428 2.198 1333464 
3 3 2.207 1287461 2.198 1298485 
4 4 2.207 1294271 2.207 1287461 
5 5 2.198 1283464 2.207 1283904 
6 6 2.207 1283921 2.207 1283854 
7 MEAN 2.204 1282574.83 2.2011 1294751.33 
8 SD 0.004 10685.87 0.007 19909.99 
9 %RSD 0.210 0.833 0.319 1.537 
 
Table 5: Linearity and Statistical analysis data for Sitafloxacin 
S. No. Concentration (µg/mL) Area Average Area Statistical Analysis 
Slope Y-Intercept Correlation Coefficient 







0.9999 2 10 992290 
3 15 1500786 
4 20 1989536 
5 25 2475634 
  
Table 6: Robustness results of the proposed RP-HPLC method 
S. No. Parameters Peak Areas Retention Time (Rt) USP 




Flow rate (±0.2) 
 
0.9 mL/min 
0.7 1495177 2.465 2639 1.396 
0.9 1318938 2.198 2615 1.423 









1468912 2.421 2594 1.394 
30 1318938 2.198 2615 1.423 
35 1167859 2.018 2569 1.685 
 
3 
Mobile phase composition (± 5%)  
70:30 
65:35 1412799 2.357 2608 1.393 
70:30 1318938 2.198 2615 1.423 
75:25 1179849 1.973 2457 1.648 
 
Limit of Detection: The limit of detection (LOD) has established the 
minimum concentration at which the analyte can be reliably 
detected. LOD is determined by the signal to noise ratio and 
generally acceptable detection limit ratio is 3:1 and it was found to 
be 0.429 μg/mL. 
Limit of Quantification: The limit of quantification (LOQ) has 
established the minimum concentration at which the analyte can be 
reliably quantified. LOQ is determined by the signal to noise ratio 
and a typical signal to noise ratio is 10:1 is acceptable for estimating 
the quantification limit and it was found to be 1.415 μg/mL. Finally 
Potnuri et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 9, 552-555 
555 
the proposed method is having good system suitability and its parameters were shown in Table 7. 
 
Table 7: System suitability parameters of proposed RP-HPLC method 
S. No. Parameters Values 
1 Wavelength (λ max) 300 nm 
2 Linearity range(μg/mL) 5-25 
3 Regression equation Y=98824x+11140 
4 Correlation coefficient(r2 0.9999 ) 
5 Retention time (minutes) 2.198 
6 Theoretical plates 2615 
7 Tailing factor 1.423 
8 Limit of Detection (μg/mL) 0.429 
9 Limit of Quantification (μg/mL) 1.415 
10 Asymmetry Factor 1.672 
11 Capacity factor (k) 0.147 
 
CONCLUSION 
A RP-HPLC method for quantitative estimation of SFX in bulk and 
pharmaceutical dosage forms is established. The method is simple, 
accurate, linear, sensitive and reproducible as well as economical for 
the effective quantitative analysis of SFX in bulk and tablet dosage 
forms. The method was validated, and all the method validation 
parameters were tested and shown to yield satisfactory results. The 
method is free from interactions of the other ingredients and 
excipients used in the tablet formulations. Finally it is concluded that 
the method is suitable for use in the routine quality control analysis 
of Sitafloxacin in API and in pharmaceutical dosage forms. 
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